[go: up one dir, main page]

NO20003813L - FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav - Google Patents

FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav

Info

Publication number
NO20003813L
NO20003813L NO20003813A NO20003813A NO20003813L NO 20003813 L NO20003813 L NO 20003813L NO 20003813 A NO20003813 A NO 20003813A NO 20003813 A NO20003813 A NO 20003813A NO 20003813 L NO20003813 L NO 20003813L
Authority
NO
Norway
Prior art keywords
spicamycin
procedures
derivatives
reducing
preventing pain
Prior art date
Application number
NO20003813A
Other languages
English (en)
Other versions
NO20003813D0 (no
Inventor
David Borsook
Jeffrey William Clark
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of NO20003813L publication Critical patent/NO20003813L/no
Publication of NO20003813D0 publication Critical patent/NO20003813D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Fremgangsmåter for å gi smertelindring, som innbefatter de trinn å identifisere et dyr som trenger smertelindring, og å administrere en mengde av en forbindelse med formel (II) som er tilstrekkelig til å gi smertelindring.
NO20003813A 1998-01-26 2000-07-25 FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav NO20003813D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/013,711 US5905069A (en) 1998-01-26 1998-01-26 Methods of decreasing or preventing pain using spicamycin or derivatives thereof
PCT/US1999/001518 WO1999037310A1 (en) 1998-01-26 1999-01-26 Methods of decreasing or preventing pain using spicamycin or derivatives thereof

Publications (2)

Publication Number Publication Date
NO20003813L true NO20003813L (no) 2000-07-25
NO20003813D0 NO20003813D0 (no) 2000-07-25

Family

ID=21761335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003813A NO20003813D0 (no) 1998-01-26 2000-07-25 FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav

Country Status (9)

Country Link
US (1) US5905069A (no)
EP (1) EP1051182A1 (no)
JP (1) JP4712968B2 (no)
KR (1) KR20010040413A (no)
CN (1) CN1146430C (no)
AU (1) AU758342B2 (no)
CA (1) CA2317577A1 (no)
NO (1) NO20003813D0 (no)
WO (1) WO1999037310A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
DE60144383D1 (de) * 2000-09-20 2011-05-19 Gen Hospital Corp Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
WO2002036127A2 (en) * 2000-10-31 2002-05-10 Nutrition 21, Inc. Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes
PT1423168E (pt) * 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
WO2006039416A2 (en) * 2004-10-01 2006-04-13 The Mclean Hospital Corporation Cns assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
JP5753784B2 (ja) * 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
JP2015524482A (ja) * 2012-08-09 2015-08-24 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を含む組成物およびその使用方法
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015811A1 (fr) * 1989-06-16 1990-12-27 Kirin Beer Kabushiki Kaisha Spicamycine x et son utilisation
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤

Also Published As

Publication number Publication date
EP1051182A1 (en) 2000-11-15
AU758342B2 (en) 2003-03-20
CN1146430C (zh) 2004-04-21
CN1289250A (zh) 2001-03-28
AU2469399A (en) 1999-08-09
JP2002501028A (ja) 2002-01-15
WO1999037310A1 (en) 1999-07-29
CA2317577A1 (en) 1999-07-29
NO20003813D0 (no) 2000-07-25
US5905069A (en) 1999-05-18
KR20010040413A (ko) 2001-05-15
JP4712968B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
AU5624699A (en) Use of 5ht-6 antagonists
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20003813L (no) FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
NO20003758L (no) Trekonserveringsmidler
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
NO20005588L (no) Inhibisjon av Helicobacter Pylori proliferasjon
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AU2001291133A1 (en) Methods of decreasing or preventing pain using spicamycin derivatives
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
PT1137438E (pt) Preparado com espectro terapeutico melhorado, contendo inibidores da sintese de nucleotidos
NZ526394A (en) Sodium channel modulators derived from 2-piperidylimidazoles
AU2003238232A1 (en) Compositions and methods for preventing, treating and diagnosing diabetes
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
NZ513603A (en) ADP-ribosylation inhibitors and remedies for endotoxic bacterial enteric infection containing proanthocyanidin as the active ingredient
BR0011742A (pt) Proteção bacteriana
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
BR9612245A (pt) Inibidor de óxido nitrico (no) sintase para tratamento ou prevenção de diabetes tipo ii

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application